205 related articles for article (PubMed ID: 37080833)
1. Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate: A retrospective cohort study.
Lowentritt B; Pilon D; Waters D; Rossi C; Muser E; Kurteva S; Shah A; Khilfeh I; Du S; Ellis L; Lefebvre P; Brown G
Urol Oncol; 2023 May; 41(5):252.e19-252.e27. PubMed ID: 37080833
[TBL] [Abstract][Full Text] [Related]
2. Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamide.
Lowentritt B; Pilon D; Khilfeh I; Rossi C; Muser E; Kinkead F; Waters D; Ellis L; Lefebvre P; Brown G
Urol Oncol; 2023 May; 41(5):253.e1-253.e9. PubMed ID: 37061452
[TBL] [Abstract][Full Text] [Related]
3. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.
Saad F; Efstathiou E; Attard G; Flaig TW; Franke F; Goodman OB; Oudard S; Steuber T; Suzuki H; Wu D; Yeruva K; De Porre P; Brookman-May S; Li S; Li J; Thomas S; Bevans KB; Mundle SD; McCarthy SA; Rathkopf DE;
Lancet Oncol; 2021 Nov; 22(11):1541-1559. PubMed ID: 34600602
[TBL] [Abstract][Full Text] [Related]
4. Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study.
Matsubara N; Chi KN; Özgüroğlu M; Rodriguez-Antolin A; Feyerabend S; Fein L; Alekseev BY; Sulur G; Protheroe A; Li S; Mundle S; De Porre P; Tran N; Fizazi K
Eur Urol; 2020 Apr; 77(4):494-500. PubMed ID: 31843335
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study.
Posadas EM; Chi KN; de Wit R; de Jonge MJA; Attard G; Friedlander TW; Yu MK; Hellemans P; Chien C; Abrams C; Jiao JJ; Saad F
Clin Cancer Res; 2020 Jul; 26(14):3517-3524. PubMed ID: 32366670
[TBL] [Abstract][Full Text] [Related]
6. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
[TBL] [Abstract][Full Text] [Related]
7. The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels.
Werutsky G; Maluf FC; Cronemberger EH; Carrera Souza V; Dos Santos Martins SP; Peixoto F; Smaletz O; Schutz F; Herchenhorn D; Santos T; Mavignier Carcano F; Queiroz Muniz D; Nunes Filho PRS; Zaffaroni F; Barrios C; Fay A
BMC Cancer; 2019 May; 19(1):487. PubMed ID: 31122212
[TBL] [Abstract][Full Text] [Related]
8. Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer.
Chowdhury S; Bjartell A; Agarwal N; Chung BH; Given RW; Pereira de Santana Gomes AJ; Merseburger AS; Özgüroğlu M; Juárez Soto Á; Uemura H; Ye D; Brookman-May SD; Londhe A; Bhaumik A; Mundle SD; Larsen JS; McCarthy SA; Chi KN
Ann Oncol; 2023 May; 34(5):477-485. PubMed ID: 36858151
[TBL] [Abstract][Full Text] [Related]
9. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
Smith MR; Saad F; Rathkopf DE; Mulders PFA; de Bono JS; Small EJ; Shore ND; Fizazi K; Kheoh T; Li J; De Porre P; Todd MB; Yu MK; Ryan CJ
Eur Urol; 2017 Jul; 72(1):10-13. PubMed ID: 28314611
[TBL] [Abstract][Full Text] [Related]
10. Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
de Bono JS; Chowdhury S; Feyerabend S; Elliott T; Grande E; Melhem-Bertrandt A; Baron B; Hirmand M; Werbrouck P; Fizazi K
Eur Urol; 2018 Jul; 74(1):37-45. PubMed ID: 28844372
[TBL] [Abstract][Full Text] [Related]
11. Real-world prostate-specific antigen response and progression to castration-resistant prostate cancer among men with metastatic castration-sensitive prostate cancer treated with apalutamide: a multi-institutional study in the Chu-shikoku Japan Urological Consortium.
Tohi Y; Kato T; Kobayashi K; Daizumoto K; Fukuhara H; Ohira S; Katayama S; Shimizu R; Takamoto A; Nishimura K; Ikeda K; Nagami T; Hayashida Y; Hirama H; Naito H; Tomida R; Sasaki Y; Yamamoto S; Shimizu S; Sugimoto M;
Jpn J Clin Oncol; 2024 Feb; 54(2):167-174. PubMed ID: 37840362
[TBL] [Abstract][Full Text] [Related]
12. Clinical Outcomes of First Subsequent Therapies After Abiraterone Acetate Plus Prednisone for High-Risk Metastatic Castration-Sensitive Prostate Cancer in the LATITUDE Study.
Koroki Y; Taguri M
Target Oncol; 2023 Jan; 18(1):119-128. PubMed ID: 36443540
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study.
Kobayashi K; Okuno N; Arai G; Nakatsu H; Maniwa A; Kamiya N; Satoh T; Kikukawa H; Nasu Y; Uemura H; Nakashima T; Mikami K; Iinuma M; Tanabe K; Furukawa J; Kobayashi H
Jpn J Clin Oncol; 2021 Apr; 51(4):544-551. PubMed ID: 33324967
[TBL] [Abstract][Full Text] [Related]
14. [Early- vs. late-onset treatment using abiraterone acetate plus prednisone in chemo-naïve, asymptomatic or mildly symptomatic patients with metastatic CRPC after androgen deprivation therapy].
Merseburger AS; Rüssel C; Belz H; Spiegelhalder P; Feyerabend S; Tran N; Kruetzfeldt K; Baurecht W; Bögemann M
Aktuelle Urol; 2020 Dec; 51(6):562-571. PubMed ID: 32268436
[TBL] [Abstract][Full Text] [Related]
15. Clinical effect of abiraterone acetate in Korean patients with metastatic castration-resistant prostate cancer according to duration of androgen deprivation therapy.
Kim KB; Jo JK; Ahn S; Lee S; Jeong SJ; Hong SK; Byun SS; Lee SE
Korean J Urol; 2015 Aug; 56(8):580-6. PubMed ID: 26279827
[TBL] [Abstract][Full Text] [Related]
16. Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status.
Azad AA; Eigl BJ; Leibowitz-Amit R; Lester R; Kollmannsberger C; Murray N; Clayton R; Heng DY; Joshua AM; Chi KN
Eur Urol; 2015 Mar; 67(3):441-7. PubMed ID: 24508071
[TBL] [Abstract][Full Text] [Related]
17. Early prostate-specific antigen response among Black and non-Black patients with advanced prostate cancer treated with apalutamide.
Bivins VM; Durkin M; Khilfeh I; Rossi C; Kinkead F; Waters D; Lefebvre P; Pilon D; Ellis L
Future Oncol; 2022 Oct; 18(32):3595-3607. PubMed ID: 36196743
[No Abstract] [Full Text] [Related]
18. The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer.
Ryan CJ; Crawford ED; Shore ND; Underwood W; Taplin ME; Londhe A; Francis PSJ; Phillips J; McGowan T; Kantoff PW
J Urol; 2018 Aug; 200(2):344-352. PubMed ID: 29630978
[TBL] [Abstract][Full Text] [Related]
19. Duration of Treatment in Prostate Cancer Patients Treated with Abiraterone Acetate or Enzalutamide.
Pilon D; Behl AS; Ellis LA; Emond B; Lefebvre P; Dawson NA
J Manag Care Spec Pharm; 2017 Feb; 23(2):225-235. PubMed ID: 28125362
[TBL] [Abstract][Full Text] [Related]
20. Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world retrospective study.
Zhao JG; Liu JD; Shen PF; Tang X; Sun GX; Zhang XM; Chen JR; Shu KP; Shi M; Zeng H
Asian J Androl; 2018; 20(6):545-550. PubMed ID: 30106011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
